Researchers discovered that semaglutide (Ozempic/Wegovy) protects the liver through a previously unknown mechanism that doesn't depend on weight loss. The drug directly targets specialized blood vessel cells called liver sinusoidal endothelial cells (LSECs) that line the liver's tiny blood vessels. In mice with fatty liver disease, semaglutide improved liver inflammation, scarring, and fat accumulation even when weight loss was blocked. The study used advanced genetic techniques to map exactly which cells respond to the drug, revealing that LSECs act as master coordinators of liver repair.
